Search Results

Pharm Country

Vela Diagnostics Collaborates with SRL Inc. for Product Distribution in Japan

Vela Diagnostics announced a research collaboration with SRL Inc, a premier Japanese healthcare service company.

October 2, 2023

·

2 min read

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics today announced that the first patients have been screened at a U.S. trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS).

May 16, 2024

·

13 min read

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus, for research use only.

July 26, 2022

·

2 min read

Drug Development

Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya

Vela Diagnostics has announced its appointment by the National Public Health Laboratory of Kenya as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund.

August 3, 2022

·

3 min read

Pharm Country

Vela Diagnostics Launches Multiplex PCR-Based Test for Detecting UTI Pathogens and Antimicrobial Resistance Genes

Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*).

May 17, 2022

·

3 min read

Drug Development

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.

March 28, 2023

·

5 min read

Drug Development

Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.

February 10, 2023

·

6 min read

Press Releases

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 18, 2024

·

1 min read

Pharm Country

Media Pooling Strategy to Increase Testing Throughput Added to Vela Diagnostics’ ViroKey SARS-CoV-2 RT-PCR Test v2.0

Vela Diagnostics has announced that its ViroKey® SARS-CoV-2 RT-PCR Test v2.0 now has the additional capability to be used for pooling, using a three-in-one media pooling strategy.

April 22, 2022

·

2 min read

Policy

Radical Imaging Announces FDA Clearance for FlexView Diagnostic, its SaaS Image Viewer for Diagnostic Use.

Radical Imaging, a trailblazer in medical imaging viewer solutions, proudly announces that FlexView Diagnostic, its SaaS web DICOM viewer product, received FDA clearance for diagnostic use.

June 24, 2024

·

2 min read